Key Takeaways
- • IGIS Asia Investment Management and CHA Bio Group announced a strategic partnership to establish an Asia-Pacific life science real estate investment platform, targeting R&D, manufacturing, and healthcare facilities across the region.
- • IGIS aims to establish Korea Life Science Investment Platform (KLSIP), the first Korea-focused investment vehicle dedicated to life science real estate, with an initial target of $350 million in assets under management.
- • The venture will leverage IGIS's real estate transaction expertise and CHA Bio Group's deep knowledge of the biopharma industry to secure first-mover advantage in an underserved market segment across South Korea and overseas.
- • The platform will develop and invest in high-quality life science assets including R&D facilities, manufacturing plants, hospitals, medical offices, and healthcare centers to support companies ranging from biotech incubators to multinational pharmaceutical groups.
- • The partnership positions both entities to capitalize on robust growth in the Asia-Pacific life science sector by providing specialized real estate solutions tailored to rapidly evolving industry demands.
Summary
IGIS Asia Investment Management, the pan-Asian investment arm of South Korea's largest real estate investment manager, has partnered with CHA Bio Group, one of South Korea's largest and oldest biopharma conglomerates with substantial global operations, to launch a dedicated life science real estate investment platform for the Asia-Pacific region. The announcement, made on February 16, 2023, represents a strategic combination of complementary expertise: IGIS brings its proven track record in real estate transactions while CHA contributes specialized knowledge of the pharmaceutical and biotechnology industries.
The venture targets $350 million in assets under management during its initial phase and plans to develop and invest in specialized life science real estate across metropolitan centers in South Korea and other Asia-Pacific markets. The platform will focus on high-quality assets including R&D facilities, manufacturing plants, hospitals, medical offices, and broader healthcare infrastructure. By combining these property types under one investment platform, the venture aims to address the multifaceted and rapidly evolving real estate needs of life science companies operating across the development and commercialization spectrum—from early-stage biotech incubators to multinational pharmaceutical corporations.
IGIS plans to establish Korea Life Science Investment Platform (KLSIP), the first Korea-focused investment vehicle dedicated exclusively to life science real estate. This dedicated vehicle will serve as the primary capital deployment mechanism for the venture, ensuring sufficient capitalization to meet growing demand in South Korea's expanding life science sector. Both partners view this platform as a catalyst for accelerating robust sector growth throughout Asia-Pacific by removing barriers to real estate access and providing tailored facilities designed for the industry's specific operational and regulatory requirements. The partnership's first-mover positioning in this specialized real estate niche aims to establish competitive advantage in a market segment that has received limited dedicated institutional attention to date.
The venture targets $350 million in assets under management during its initial phase and plans to develop and invest in specialized life science real estate across metropolitan centers in South Korea and other Asia-Pacific markets. The platform will focus on high-quality assets including R&D facilities, manufacturing plants, hospitals, medical offices, and broader healthcare infrastructure. By combining these property types under one investment platform, the venture aims to address the multifaceted and rapidly evolving real estate needs of life science companies operating across the development and commercialization spectrum—from early-stage biotech incubators to multinational pharmaceutical corporations.
IGIS plans to establish Korea Life Science Investment Platform (KLSIP), the first Korea-focused investment vehicle dedicated exclusively to life science real estate. This dedicated vehicle will serve as the primary capital deployment mechanism for the venture, ensuring sufficient capitalization to meet growing demand in South Korea's expanding life science sector. Both partners view this platform as a catalyst for accelerating robust sector growth throughout Asia-Pacific by removing barriers to real estate access and providing tailored facilities designed for the industry's specific operational and regulatory requirements. The partnership's first-mover positioning in this specialized real estate niche aims to establish competitive advantage in a market segment that has received limited dedicated institutional attention to date.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.